REGISTERED COMPANY NUMBER.. 02361986 (England and Wales)
REGISTERED CHARITY NUMBER: 801279
THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIM￿ED
la company limited by guarantee)
REPORT OF THE TRUSTEES AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
Wenn Townsend
Chartered Accountants
Oxford

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED
REFERENCE AND ADMINISTRATIVE DETAILS
Registered company number.. 02361986 (England and Wales)
Registered charity number.. 801279
Trustges:
Miss M Ainsworth-wells
MrESDale
Mr N H Riley (resigned 3 March 20251
Dr C B Shepherd
Mr D A Allen
Mr M Mitchell
Registered office:
Unit 7 Apollo Office Court
Radclive Road
Gawcott
Buckingham
Buckinghamshire
MK184DF
Auditors:
Wenn Townsend
30 Sl Giles
Oxford
OX13LE

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED
CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
Page
Report of the Trustees
1to9
Report of the Independent Auditors
101012
Statement of Financial Activities
13
Balance Sheet
14
Statement of Cash Flows
15
Notes lo the Statement of Cash Flows
16
Notes lo the Accounts
171028
Detailed Statement of Financial Actwities
29

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2025
The Iruslees who are also directors of the charity for the purposes of the Companies Act 2006, present
their report with the audited financial slalemenls of the charity for the year ended 31 December 2025.
The trustees have adopted the provisions of the Statement of Recommended Practice ISORPI
"Accounting and Reporting by Charities in preparing the annual report and the financial statements of
the Charity.
OBJECTIVES AND ACTIVITIES
Charitable Objectives
The charity's vision is to improve the quality of life for those affected by MEICFS. We do this by providing
support and information", funding research lo find biomedical markers and treatments and educating and
informing the broad eco-system that includes media, politicians, educators, health and social care
providers and the commercial sector.
What we do and why we do It
The ME Association is one of the leading national charities for people with MEICFS (Myalgic
Encephalomyelitis or Encephalopathy., Chronic Fatigue Syndrome) and it is also the longest running
UK charity, having been founded in 1980.
In the last 45 years, we have established an excellent reputation and consistently deliver high standards
of support, reliable and timely information, effective lobbying, influencing, and we continue lo raise
awareness of MEICFS within the public and lo help further educate health care and social care
professionals.
Over the years, the ME Association has funded a range of medical research studies in the hope they
may find a biomarker or an effective treatment for the disease. As there are important clinical
and pathological overlaps be￿een MEICFS and Long Covid, we also provide information for people
who have this condition post the Covid19 pandemic.
MEICFS is mulli-systemic disease and around 400,000 people in the UK have this debilitating illness
with an estimated 1.8m having Long Covid. Symptoms include profound fatigue, sleep disturbance,
post-exertional malaise, cognitive difficulties and a range of other symptoms like pain, headaches,
nausea and intolerance lo lights and noise. These are life-changing and indiscriminate medical
conditions that affect both adults and children regardless of socio-economic or ethnic background.
MEICFS is a doubly invisible illness." not only are symptoms hard to see but the disease attraels little
understanding from the public or the Medical profession. This leads lo people with MEICFS
experiencing prejudice and disbelief, making them feel stigmatised and isolated.
MEICFS can lead to long-lerm disability and a lower quality of life than Multiple Sclerosis or Cancer.
It most often presents as a complex post-infeclion syndrome that dramatically impacts a person's
ability to complete everyday tasks and to mobilise normally. Long Covid affects people in a similar
way.
There are no effective drug Irealments, but convalescence and appropriate self-managemenl can help
stsbilise and improve functional ability over lime for some people. Complete recovery from MEICFS
is rare and for people who are severely affected the disease can be life-changing and in some cases
life-threalening.
Support & Information
We provide support and information for.. People with a diagnosis of MEICFS & Long Covid.. SLJb-
groups." 25 % severe and very severe ME,. 75'/o moderates to mild., People with symptoms bul no
diagnosis., Carers, Family members, Friends.
Information covers". Daily life with MEICFS & Long Covid", Understanding MEICFS & Long Covid", Early
and Accurate Diagnosis", Managing MEICFS & Long Covid, Provision of and access to information on
good management and social care INICEI,. Awareness and Recognition (Remove Stigmal,. Benefits
awareness and accessibility,. Employment and Education,. Outcomes of research that may be relevant
to the management of those with MEICFS. Progress with research - what's coming up,. How to care
for someone with MEICFS.

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2025
OBJECTIVES AND ACTIVITIES Icontinuedl
We identify the most relevant information and appropriate channels, platforms, partners and people
in order lo reach people with MEICFS and those with symptoms but no diagnosis.. those who care for
them and support them., intermediaries from whom they may seek support and information.
These include".
A safe and welcoming Membership community for people affected by these conditions who
come together and benefit from sharing their experiences.
A comprehensive website, and large range of free downloadable literature, covering all
aspects of life with MEICFS and Long Covid.
The ME Connect telephone information and support service and by responding effectively to
a g￿al many email and social media ￿qUeStS for help.
A membership magazine IME Essenliall, newsletter and our website and social media
platforms.
Educatlng & Influenclng
Our audience includes.. Healthcare Professionals I Social Care Professionals., Medical Professional
organisalions. e.g. The Medical Royal Colleges., The NHS (Primary & Secondary Carel., Parliament.,
Media (Publicl . All UK Govts., Healthcare commissioners.
Information provision includes.. Diagnosis of MEICFS, the Importan￿ of having an Early and Accurate
Diagnosis,. The 2021 NICE Guideline Recommendations,. How lo improve and create good specialist
services., How to develop effective clinical pathways,. How to generate good care and support plans,.
How lo provide ongoing care and support In primary & secondary care, and social care servicesl
DHSC prioritising MEICFS., Awareness and Recognition (Remove Sligmal", Benefits awareness and
accessibility l Employment and Education., Outcomes of research that may be relevant to the
management of those with MEICFS. Progress with research
We identify the most appropriate channels, platforms, partners and people lo reach health & social
care,. political,. media., employment, insurance & pension professionals and bodies in and outside the
field of MEICFS.
These include..
A dedicated Health and Social Care team who both respond to and actively approach the health
and social care sector
Medical Matters- a medical magazine for health professionals
A dedicated Press Officer who responds to media enquiries and drives media through the
placement of stories across appropriate media platforms
Collaboration and support for Forward-ME, the ME Research Collaborative, DecodeME, The
All-Party Parliamentary Group on ME, Chronic Illness Inclusion, and UK Long Covid initiatives.
Campaigns targeted lo raise awareness and bring about positive change within medical
sellings such as GP surgeries and as campaign partners for the national 'Carers' Week,

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2025
Research
Our primary audience includes. Research professionals IMEICFS & Long covidl., Research
professionals Inon-MEICFS & Long ¢ovidl and Secondary las a route lo the above).. ME Research
Collaborative,. MRC., NIHR., Pharmaceutical Companies ,' Other research funding charities.
Information includes". The role of the MEA & access lo our research funds including Ramsay Research
Fund," MEICFS & Long Covid," Vlthy research is critical." Understanding causellriggers, Understanding
perpelualion," Developing effective treatments," What biomedical research has been done already and
what is missing. We identify the most appropriate channels, platforms, partners and people lo reach
research professionals in and outside the field of MEICFS and issue grants and contracts lo relevant
projects.
These include..
The MEA Ramsa
Research Fund funds biomedical research into cause and management of
MEICFS. This includes all the basic running costs for the MEICFS Biobank at the Ro al Free
Hos
ital in London which collects blood samples and anonymised clinical data from people with
MEICFS, Multiple Sclerosis IMS) and healthy controls.
The ME Association also works with the Manchester Brain Bank on post-mortem research. This
arrangement means that we will be able lo obtain pathological information about specific parts
of the brain, spinal cord and dorsal root 9anglia where symptoms, abnormalities and
neuroimaging studies have already indicated they could be involved in causing or perpetuating
the disease.
The ME Association is funding or considering funding almost every research group in the UK
that is carrying out biomedical research into the cause or management of MEICFS - a total of
12 different centres or individuals.
This includes, in December 2025, Imperial College London being awarded £1.1 million by The
ME Association to lead the Rosetta Stone study, the largest research project of ils kind which
will enable lop scientists in their field to conduct side-by-side cellular and molecular analyses
of MEICFS and Long Covid
offering an Unpre￿dented look into what these conditions
share and taking us closer to diagnostic biomarkers and treatment pathways.
Public benefit
In preparing these financial statements and their report, the Trustees confirm that they have had regard
to the Charity Commission's guidance on public benefit. and that they consider the objectives and
activities of the charity have historically and continue to fall within the scope of that guidance.
Fundraising standards information
As part of the overall 5-year fundraising strategy the approach for 2025 was to continue and strengthen
a range of fundraising methods so that the charity was not dependent on one type. This included
increasing the challenge event portfolio, introducing new community fundraising products, developing
major donor relations and creating a trusts programme.
The charity is a member of the Fundfftising Regulator and conducts all fundraising activities using the
Codes of Practice and Fundraising Promise. Additionally, all fundraising staff currently hold
qualifications through the Chartered Institute of Fundraising. There have been no instances of failure lo
comply with the fundraising codes of practice or the fundraising promise.
All charity fundraisers are asked to register their detsils with the charity. Regular communication follows
ensure both legal and best practice is adhered to within any fundraising activities. There were no
complaints received by the charity from fundraising activities in 2025.
The charity's fundraising activities operate within the published privacy policy. All activities are carried
out using the Fundraising Regulators guidelines on consent and data protection, see section 5.2
Safeguarding and working with people in vulngrable Gircumslances.
The charity does not employ external fundraising agencies to solicit donations from members of the
public. All volunteer fundraisers are advised to adhere to the Fundraising Regulators, guidelines.

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2025
ACHIEVEMENTS AND PERFORMANCE
2025 was another significant year for the MEA. A year marked by meaningful progress, ongoing
challenges, and renewed determination in our mission lo Improve the lives of people with Myalgic
Encephalomyelitis IMEI, including those living with post-infectious conditions and Long COVID that
overlap with MEICFS.
Support
Supporting our community remains the heart of our work. Demand for our services continued to grow,
particularly among individuals with severe or very severe ME and those newly affected following
viralllriggering illnesses.
Our support line, information services, and online resources remain a lifeline for thousands, offering
trusted guidance, emotional support, and praclieal help al every stage of illness. This year, we also
launched new educational materials focusing on pacing, symptom management, and navigating
disability and workplace rights, along with the launch of a dedicated panel for those severely affected.
Educate and Influence
Throughout the year, the ME Association has continued to sland fimily with people whose voices are
often unheard. We intensified efforts lo ensure that policymakers, healthcare leaders, and research
institutions understand the urgent need for better services, compassionate care pathways, and
increased biomedical funding.
Our submissions lo government consultations, participation in advisory groups, and public-facing
campaigns have helped place MEICFS firmly on the national health agenda. Although systemic change
remains gradual, our Influen￿ continues to build.
Raising awareness and public understanding is essential to improving quality of life for people with
MEICFS. In 2024-25, we expanded our digital outreach, engaged new audiences through community
events and public campaigns, and strengthened partnerships with employers and healthcare
organisalions.
ME Awareness Month featured our mostvisible campaign yet, amplifying patient stories and highlighting
the profound impact of this illness and our participation in Carers, week 2025 pul those who support
people with MEICFS in the heart of Parliament.
In September, we hosted our Lives We Cannot Live exhibition at London's Oxo Gallery, in partnership
with filmmaker and photographer Jeremy Jeffs. It generating over £150,000 in free publicity, reaching
new audiences.
We are working with the DHSC and NHS England on progressing several important actions from the
DHSC Delivery Plan on MEICFS. These include helping lo prepare a template service specification
for the specialist MEICFS referral clinics, setting up a national referral service for people with very
severe MEICFS who require hospitsl admission, and working with the Royal College of Physicians on
various medical education initiatives.
Research
202￿25 saw significant strides in biomedical resea￿h, supported by the continued generosity of our
members and donors. We expanded grants to studies exploring immune dysfunction, post-infectious
triggers, autonomic impairment, and potential biomarkers, while pursuing collaborations with clinicians
and scientists nationally and inlernationalty. These efforts contribute to a growing global network
etermined lo unravel the complex biology of ME.
We are committing nearly £2 million to research over the next three years, including £1.1 million for the
Rosetta Stone study, the largest single investment in biomedical research ever made by a UK charity
in this field. This groundbreaking work aims to help wodd-leading scientists uncover shared pathways
between MEICFS and Long COVID.

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2025
ACHIEVEMENTS AND PERFORMANCE {continuedl
Operational Resilience and Governance
Behind the s￿nes, the Association has continued to prioritise governance. financial sustainability, and
operational efficiency.
Following discussions at the December 2024 AGM, we commissioned an independent governance
review of the charity. The review produced 49 recommendations, ranging from minor procedural
updates to substantial long-term structural changes. The new organisational structure and enhanced
stmtegic focus reflects a large proportion of the recommendations, with the remaining being targeted
for completion in 2026-7.
The charity's financial position remains positive. However, with increasing demands from additional
stsffing and the awarding of significant research grants, we are operating sustainably on our current
reserves and have restructured our management framework lo focus on financial management and
income generation via the creation of two new Director roles. A continual review of the organisational
structure, including roles such as Chief Executive OffI￿r or Chief Operating Officer, will be undertaken
when financially and strategically viable. Over the next 12 months however, our campaigns will place a
strong emphasis on income generation lo support our work and secure long-lerm sustainability.
We have also invested in new digital infrastructure, improved reporting and transparency, and
strengthened volunteer engagement. These initiatives enable us to better serve our members and
position the organisation for long-lerm stability and growth.
Looking Ahead
The coming year presents both challenges and opportunities. Our priorities for 2026 include..
Pushing for equitable healthcare,
Accelerating biomedical research,
Maintaining support services, and
Ensuring that every person with MEICFS feels seen, believed, and valued.
th our major commitment to research, the next 12 months will emphasise consolidation, allowing
income streams to stabilise and providing space for necessary restructuring.

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2025
Financial review
In 2025, The ME Association saw total funds decrease by £341,053 bringing the year end balance to
£3.520, 817.
Income
Total income for the year was down by £223.715 compared lo 2024, which is a result of significantly
lower legacy income but is offset by higher donations and fundraising income.
Membership subscription income remained consistent with 2025 levels. Vvhile this represents a
relatively modest portion of our overall revenue, membership contributions continue playing a
meaningful role in supporting the day-104ay operations of the charity.
We saw a decrease in legacy income in 2025. The total for legacy income re￿iVed in the year was
£296,533 compared with £628,031 in 2024. Legacies remain a vital and appreciated source of funding
for our work. We are deeply grateful to all supporters who remember the ME Association in their wills.
Unless any donation, legacy or fundraising income is expressly reslricled lo the purpose of funding
research activities, all income is allocated to the charity's general funds. These general funds can be
applied towards research activities alongside restricted funds when appropriate.
Expenditure
Total expenditure increased by £370.398 compared with the previous year.
In 2025 we spent an additional £142k on research compared with 2024. A fvll breakdown of reSea￿h
expenditure can be foLJnd in the notes lo the accounts.
We continued to expand our teams across Fundraising, ME Connect, the Health & Social care team and
engaged with a PR consultant which reSu￿ed in higher stsff and contractor costs in the year.
The Audit, Investment and Risk Committee met regularly throughout the year to oversee financial
management, improve govemance and internal controls, manage organisational risk and lo assess
research funding applications presented by the Research Committee. Their work supports the Board
in fulfilling its duties and supporting long-lerm planning for the future of the charity.
Reserves
Totsl Funds Held
Al 31 December 2025, the ME Association held total funds of £3.520.817
Investment Approach
The ME Association carefully considers all potential investments and recognises its responsibility as
steward of the funds received from our generous supporters and donors. The charity will always try to
act in the best interests of its beneficiaries and supporters.
The Trustees review reserves regularly to ensure funds are managed effectively, balancing financial
security with the need lo support the charity's objectives.
The Trustees aim to maintain reserves equivalent lo a minimum of 12 months of unrestricted
operating costs estimated at £945,000. This calculation includes unreslricled costs but excludes
reslricled research expenditure and depreciation. This would enable the charity to continue meeting
its operational and membership obligations, in the event of unforeseen circumstances or a reduction
in income.

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2025
Financial review
continued
Unrestricted funds
Unreslricled funds al year-end tolalled £2,904,690 12024.. £3,086,948), representing a decrease of
£182,258 during the year.
These funds provide flexibility lo respond to emerging needs, invest in future development, and
supplement reslricled funds when appropriate.
Restrlcted funds
The ME Association holds restricted funds solely for the purpose of financing biomedical research
into the causes, diagnosis and treatment of MEICFS. These are principally held in the Ramsay
Research Fund and must be used in line with donor intent.
As of 31 December 2025, restricted reserves stood at £616.127 12024.. £774,922), representing a
decrease of £158,795 during the year.
The charity recognises its obligation lo relain sufficient restricted reseNes lo meet both existing and
future research commitments. In the event of the charity being wound up, any remaining restricted
funds would be transferred lo a UK charity with objectives closely aligned with supporting and
publishing MEICFS research.
Freg Reserrfes
Free reserves, which are defined as unrestricted funds, excluding designated reserves and the net
book value of fixed assets, stood at £1.558.840 at 31 De￿mber 202512024.. £1,220,357).
The increase in free reserves is a result of removing core services from designated funding.
Designated Reserves
Within unrestricted funds, the ME Association has designated £1,250,000 to support specific
strategic and operational priorities..
£15,000- designated as a slnklng fund lo cover potential future repairs lo the charity's office
premises.
£235.000
designated to the general healthcare research fund for approved future
expenditure relating to the diagnosis, management, and treatment of MEICFS and Long Covid.
£1,000,000- designated for approved Research Projects. These funds have been set aside
from general reserves. Once restricted funds have been fully expended an appropriate sum
will be transferred from general reserves to restricted funds.
STRUCTURE, GOVERNANCE AND MANAGEMENT
Governing document
The charity is established under a Memorandum of Association which established the objects and
powers of the charitable company and is governed by Ils Articles of Association.
Charity constitution
The charity constitutes a limited company, limited by guarantee, as defined by the Companies Act
2006.

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2025
embership
Members subscribe annually and voting rights are based on the currency of their subscription.
Members ofthe charitable company guarantee to contribute an amount not exceeding £1 to the assets
of the charitable company in the event of winding up.
Recrultment and appolntment of new trustees
The charity is managed by elected trustees. The Articles of Association require that one third of the
trustees retire every two years bul remain eligible for re-election. Trustees are elected by the members
of the charity and must comprise of people with an interest in MEICFS.
Applications to become a trustee are advertised in both the quarterly magazine of the charity and its
social ne￿Ork media. We welcome applications from individuals who bring real-life experience,
professional skills, a willingness lo work collaboratively, and above all share our passion for improving
the lives of those living with MEICFS. There is a limit of eight Iruslees, bul the Board can co-opt up
to three additional members al any time. Co-opted trustees are then pul forward lo the membership
for election al the next annual general meeting IAGMI al which elections will lake place. Voting takes
pla￿ by either postal ballot or at the AGM.
Risk Managemont
The Trustees have conducted their own review of the major risks lo which the charity is exposed, and
systems and policies have been established to miligale those risks.
Organisational structure and how the charity makes decisions
Following a consultation al the end of 2025 the ME Association introduced a revised operating
structLJre in March 2026. Under this structured department heads and directors will work together to
develop budgets and strategic business plans. The proposals will be presented lo the board of
trustees for consideration and approval. The trustees are ￿sponSible for the overall governance
stmtegic direction of the charity.
Policies and procedures for induction and training of trustees
The charity is committed lo ensuring that new Iruslees are appropriately inducted, supported and
trained lo fulfil their responsibilities effectively. New trustees initially join the Board for a 12-monlh
period as Associate Trustees, after which they may be appointed as full Trustees if considered
suitable. They re￿1ve an induction programme designed lo familiarise them with the charity's
objectives, governance structure, strategic priorities, financial position, legal obligations, and key
policies and procedures.
Key management personnel remungration
The Iruslees are responsible for setting the remuneration of the key management personnel. Pay
levels are reviewed annually to ensure they remain fair and reasonable. In setting remuneration the
charity considers".
Responsibilities and required experien￿ for the role.
Remuneration is compared with similar size charities.
The financial position of the charity.

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2025
STATEMENT OF TRUSTEES. RESPONSIBILITIES
The Iruslees Iwho are also the directors of The Myalgic Encephalopathy Association Limited for the
purposes of company lawl are responsible for preparing the Report of the Trustees and the financial
statements in awordance with applicable law and United Kingdom Accounting Stsndards (United
Kingdom Generally Accepted Accounting Pracb"Trl.
Company law requires the trustees lo prepare financial statements for each financial year which give a
true and fair view of the stale of affairs of the charitable company and of the incoming resources and
application of resources, including the income and expenditure, of the charitable company for that
period. In preparing those financial statements, the trustees are required to
select suitable accounting policies and then apply them consistently",
observe the methods and principles in the Charity SORP 2019 IFRS1021",
make judgements and estimates that are reasonable and prudent",
slate whether applicable accounting standards have been followed.,
prepare the financial statements on the going concem basis unless il is inappropriate to
presume that the charitable company will continue in business.
The trustees are responsible for keeping adequate accounting records which disclose with reasonable
accuracy al any lime the financial position of the charitable company and lo enable them to ensure that
the financial statements comply with the Companies Act 2006. They are also responsible for
safeguarding the assets of the charitable company and hen￿ for taking reasonable steps for the
prevention and detection of fraud and other irregularities.
In so far as the Iruslees are aware..
there is no relevant audit infomialion of which the charitable company's auditors are unaware,.
and
the Iruslees have taken all steps that they ought to have taken lo make themselves aware of
any relevant audit information and lo establish that the auditors are aware of that information.
AUDITORS
The auditors, Wenn Townsend, will be proposed for re-appointment al the forthcoming Annual General
Meeting.
This report has been prepared having taken advantage of the small companies exemption in the
Companies Act 2006.
Approved by order of the board of trustees, as the company directors, on 23rd June 2026 and signed on
the board's behalf by".
Mr D A Allen- Trustee

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF
THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED
Opinion
We have audited the financial statements ofThe Myalgic Encephalopathy Association Limited Ithe'charitable
company'l for the year ended 31 December 2025 which comprise the Statement of Financial Activities, the
Balan￿ Sheet, the Cash Flow Statement and notes lo the financial slalemenls, including a summary of
significant accounting policies. The financial reporting framework that has been applied in their preparation Is
applicable law and United Kingdom Accounting Standards (United Kingdom Generalty A¢￿pIed Accounting
PracliTrl, including Financial Reporting Standard 102'The Financial Reporting Standard applicable in the UK
and Republic of Ireland,.
In our opinion the financial stslemenls..
give a true and fair view of the state of the charitable company s aff8irs as 8t 30 December 2025, and of
its incoming resources and appliealion of resources, including its income and expenditure for the year
then ended",
have been properly p￿pared in accordance with United Kingdom Generally Accepted Accounting
Practice", and
have been prepared in aecordance with the ￿quirementS of the Companies Act 2006.
Basls for oplnlon
We conducted our audit in accordan￿ with Intemational Standards on Auditing IUKI IISAS IUKII and
applicable law. Our responsibilities under those stsndards are further described in the Auditors,
responsibilities for the audit of the financial statements section of our report. We are independent of the
charitable company in accordance with the ethical requirements that are relevant lo our audit of the financial
ststemenls in the UK, including the FRC'S Ethical Standard, and we have fulfilled our other ethical
responsibilities in accordance with these requirements. We believe that the audit evidence we have obtsined
is sufficient and appropriate to provide a basis for our opinion.
Conclusions relating to going concern
In auditing the financial stslemenls, we have concluded that the trustees, use of the going concern basis of
accounting In the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not idenlilied any material uncertainties relating to events or
conditions that, individually or collective￿, may cast significant doubl on the charitable company's ability to
continue as a going con￿rn for a period of at least ￿e1ve months from when the financial statements are
authorised for Issue.
Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the
relevant sections of this report.
Other Infomiatlon
The other information comprises the information included in the Annual Report, other than the financial
ststements and our Report of the Independent Auditors thereon. The Iruslees are responsible for the other
information.
Our opinion on the financial statements does not cover the other information and, except to the extent
otherwise explicitly staled in our report, we do not express any fom of assurance conclusion thereon.
Our responsibility is lo read the other information and, in doing so, consider whether the other information is
materially inconsistent with the financial ststemenls or our knowledge obtained in the audit or otherwise
appears lo be materially misstated. If we identify such material inconsistencies or apparent material
misslatemenls, we are required lo detemiine whether this gives rise to a material misslalemenl in the financial
statements themselves. If, based on the work we have performed, we conclude that there is a material
misslatemenl of this other information, we are required to report that fact.
We have nothing to report in this regard.
Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit..
the information given in the Report of the Trustees Iwhich includes the directors, report prepared for the
purposes of company lawl for the financial year for which the financial statements are prepared is
consistent with the financial statements., and
the directors, report has been prepared in accordan￿ with applicable legal requirements.
10

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF
THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED
Matters on which we are required to report by exception
In the light of our knowledge and understanding of the charitsble company and its environment obtained in
the course of the audit, we have not identified material misstalemenls in the directors, report.
We have nothing to report in respect of the following matters in relation to which the Companies Act 2006
requires us lo report to you if, in our opinion..
adequate accounting records have not been kept, or relums adequate for our audit have not been
received from branches not visited by us., or
the financial statements are not in agreement with the accounting records and retums., or
certain disclosures of directors, remuneration specified by law are not made,. or
we have not received all the information and explanations we require for our audit., or
the trustees were not enlilled lo prepare the financial statements in accordance with the small companies,
regime and lake advantage of the small companies, exemptions in preparing the directors, report and
from the requirement lo prepare a strategic report.
Responsibilities of trustees
As explained more fully in the Statement of Trustees, Responsibilities, the trustees Iwho are also the directors
of the charitable company for the purposes of company lawl are responsible for the preparation of the financial
slalemenls and for being satisfied that they give a true and fair view, and for such internal control as the
trustees determine is necessary lo enable the preparation of financial statements that are free from material
misslatemenl, whether due to fraud or error.
In preparing the financial statements, the Iruslees are responsible for assessing the charitable company's
ability lo continue as a going concern, disclosing, as applicable, mallers related to going concern and using
the going ¢on¢ern basis of accounting unless the Iruslees either intend to liquidate the charitable company
or to cease operations, or have no realistic alternative but lo do so.
Auditor's responsibilities for the audit of the financial Statements
Our objectives are lo obtain reasonable assurance about whether the financial ststemenls as a whole are
free from material misstalemenl, whether due lo fraud or error, and lo issue an auditor's report that Includes
our opinion. Reasonable aSSU￿nCe is a high level of assurance, but is not a guarantee that an audit
conducted in accordanee with ISAS IUKI will always detect a material misstatement when it exists.
Misslatemenls can arise from fraud or error and are considered material if, individually or in the aggregate,
they could reasonably be expected to influence the economic decisions of users taken on the basis of these
financial stalemenls.
Irregularities, including fraud, are instan￿5 of non-compliance with laws and regulations. We design
procedures in line with our responsibilities, oudined above, to detect material misstatements in respect of
irregularities, including fraud. The specific procedures for this engagement and the extent to which these are
capable of detecting irregularities, including fraud is detailed below..
Enquiry of management and those charged with governance around actual and potential liligalion and
claims.,
Enquiry of management and those charged with governance lo identify any instances of non-
Complian￿ with laws and regulations.,
Reviewing minutes of meetings of those charged with governance.,
Reviewing financial statement disclosures and testing lo supporting documentation to assess
compliance with applicable laws and regulations",
Performing audit work over the risk of management override of controls, including lesling of journal
entries and other adjustments for appropriateness, evaluating the business rationale of significant
transactions outside the normal course of business and reviewing accounting estimates for bias.
Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including
those leading to a material misstatement in the financial statements or non-compliance with regulation. This
risk increases the more that Complian￿ with a law or regulation is removed from the events and transactions
refiected in the financial statements, as we will be less likely to become aware of instances of non-complian￿.
The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves
intentional concealment, forgery, collusion, omission or misrepresentation.
A further description of our responsibilities for the audit of the financial statements is located on the Financial
Reporting Council's website al.. www.trc.org.ukJaudilorsresponsibilities. This description forms part of our
auditor's report.
11

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF
THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED
Use of our report
This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of
Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might stale to the
charitable company's members those matters we are required to slate lo them in an auditor's report and for
no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone
other than the charitable company and the charitable company's members as a body, for our audit work, for
this report, or for the opinions we have formed.
frw
Benjamin Hayes Bsc FCA (Senior Statutory Auditor)
For and on behalf of Wenn Townsend
30 St Giles
Oxford
OX1 3LE
23rd June 2026
12

00
I￿ 3
TJ
TJ rfi
TJ
CJ
Jcwo
J(r

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2025
Note
2025
2024
Cash flows from operating activities
Nel cash provided by operating activities
1213,4571
200,043
Cash flows from investing activities
Purchase of tangible fixed assets
11,9511
15,7561
Ilncreaselldecrease in term deposits
206,537
1272,3051
Interest received
161,983
98,969
Net cash provided byllused inl investing activities
366,569
1179,0921
Cash flows from flnanclng actlvltles
Interest paid
17,0401
18,0971
Net cash used in financing activities
17,0401
18,0971
Change in cash and cash equivalents
in the yoar
146,072
12,854
Cash and cash equivalents at the
beginning of the year
1,207,938
1,195,084
Cash and cash equivalents at the
end of the year
1,354,010
1,207,938
15

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED
NOTES TO THE STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2025
RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES
2025
2024
Net incomellexpenditurel for the year
las per the Statement of Financial Activities)
1341.0531
253,060
Adjustments for:
Depreciation charges
Interest re￿iVed
Interest pai
Iln¢reaselldecrease in stocks
Decrease in debtors
Increase in creditors
12.692
1161.9831
7.040
{1.5851
248.701
22,731
11,920
198,9691
8,097
690
24,022
1,223
Net cash provided by operations
213 457
200,043
ANALYSIS OF CHANGES IN NET FUNDS
Cash
flows
At 1.1.25
At 31.12.25
Net cash
Cash at bank and in hand
1,207,938
146.072
1,354,010
Liquid resources
Current asset investments
2.278.750
1206.5371
2.072.213
3,486,688
60.465
3,426,223
16

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
1 ACCOUNTING POLICIES
Basis of preparing the financial statements
The company is a company limited by guarantee. The members of the company are the Trustees named on
page 1. In the event of the company being wound up, the liability in respect of the guarantee is limited to £1 per
member ofthe company.
The charity constitutes a public benefit entity as defined by FRS 102. The financial statements have been
prepared in accordance with Accounting and Reporting by Charities.. Slalemenl of Recommended Practice
applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable
in the UK and Republic of Ireland issued in October 2019, the Financial Reporting Standard applicable in the
United Kingdom and Republic of Ireland IFRS 1021, the Charities Act 2011, the Companies Act 2006. and UK
Generally AC￿pIed Accounting Practi￿.
The financial statements are prepared on a going concern basis under the historical cost convention, modified
to include certain items al fair value. The financial statements are presented in sterling which is the functional
Cur￿ncY of the charity and rounded to the nearest £.
The significant accounting policies applied in the preparation of these financial statements are set out below.
These policies have been consistently applied to all years presented unless otherwise stated.
Income recognition
All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it
is probable that the income will be received and the amount can be measured reliably.
For donations to be recognised the charity will have been notified of the amounts and the settlement date in
writing. If there are conditions attached to the donation and this requires a level of performance before entitlement
can be obtained then income is deferred until those conditions are fully met or the fulfilmenl of those conditions
is within the control of the charity and it is probable that they will be fulfilled.
For legacies, entitlement is taken as the eadier of the date on which either., the company is aware that the probate
has been granted, the estste has been finalised and notifi'cation has been made by the executorlsl lo the Trust
that a distribution will be made, or when a distribution is received from the eslale. Receipt of a legacy, in whole
or in part, is only considered probable when the amount can be measured reliably and the company has been
notified to the executorfs intention lo make a dislribulion. Where legacies have been notified to the company, or
the company Is aware of the granting of probate, and the criteria for income recognf(ion have not been met, then
the legacy is Irealed as a contingent asset and disclosed if material.
Gifts in kind donated for distribution a￿ included al valuation and recognised as income when they are distributed
lo the projects. Gifts donated for resale are included as Income when they are sold. Donated facilities are
included al the value to the company where this can be quantified and a third party is bearing the cost. No
amounts are Included in the financial statements for services donated by volunteers.
Donated services of facilities are recognised when the company has control over the item, any conditions
associated with the donated item have been mel, the receipt of economic benefit from the use of the company
of the item is probable and that economic benefit can be measured reliably. In accordance with Charities SORP
IFRS 1021, the general volunteer lime of the Friends is not recognised and refer lo the Trustees, report for more
information about their contribution.
On receipt, donated professional services and donated facilities are recognised on the basis of the vslue of the
gift lo the company which is the amount the company would have been willing to pay to obtain seNices or
facilities of equivalent economic benefit on the open market,. a corresponding amount is then recognised in
expenditure in the period of receipt.
other income is recognised in the period in which il is recoverable and to the exlenl the goods have been
provided or on completion of the servi￿.
17

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
1 ACCOUNTING POLICIES {continued}
Expenditure recognition
Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation commilling the
charity lo that expenditure, it is probable that a transfer of economic benefits will be required in selllement and
the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and
has been classified under headings that aggregate all cost related lo the category.
Resources are expended in the furtheran￿ of the charity's objectives.
Grants payable are charged In the year when the offer is made exTrpt in those cases where the offer is
conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants
offered subject to conditions which have not been met at the year-end dale are noted as a commitment bul not
accrued as expenditure.
Support costs are those that assist the work of the charity but do not directly represent charitable activities and
include office costs, governance costs, administrative payroll costs. They are incurred directly in support of
expenditure on the objects of the charity and include project management carried out at HeadqLJarters. Vthere
support costs cannot be directly atlribuled to particular headings they have been allocated to cost of raising
funds and expenditure on charitable activities on a basis consistent with use of the resources.
Fund-raising costs are those incurred in seeking voluntary contributions and do not include the costs of
disseminating information in support of the charitable aclivilies.
Tangible fixed assets
Tangible fixed assets are stated at cost lor deemed costl or valuation less accumulated depreciation and
accumulated impairment losses. Cost includes costs directly attributable lo making the asset capable of
operating as intended. All assets costing more than £200 are capilalised.
Depreciation is provided at the following annual rates in order lo write off each asset over ils estimated useful
Leasehold property
Fixtures and fittings
Computer equipment
- Over 20 years
Over 4 year$
Over 4 years
Stocks
Stocks are valued al the lower of cost and nel realISab￿ value, after making due allowance for obsolete and
slow moving items. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads.
Debtors and creditors receivable I payable within one year
Debtors and creditors with no ststed interest rate and receivable or payable within one year are recorded at
transaction price. Any losses arising from impairment are recognised in expenditure.
Cash at bank in hand
Cash at bank in hand includes cash and short term highly liquid investments with a short maturity of three months
or less from the date of acquisition or opening of the deposit or similar account.
Cash deposits that are not readily accessible within 3 months are classified as Term deposits.
Provisions
Provisions are recognised when the charity has an obligation al the balance sheet date as a result of a past
event, it is probable that an oufflow of economic benefits will be required in selllemenl and the amount can be
reliably estimated.
18

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
1 ACCOUNTING POLICIES (continued}
Taxation
The charity is an exempt charity within the meaning of schedule 3 of the Charities Act 2011 and is considered lo
pass the tests set out in Paragraph 1 Schedule 6 Finance Act 2010 and therefore it meets the definition of a
charitable company for UK corporation tax purposes.
Fund accounting
Unreslricled funds can be used in accordance with the charitable objectives at the discretion of the trustees.
Restricted funds can only be used for particular reslricled purposes within the objects of the charity. Restrictions
arise when specified by the donor or when funds are raised for particular reslricled purposes.
Further explanation of the nature and purpose of each fund is included in the notes lo the financial statements.
Operating leases
Rentals under operating leases are charged to the Statement of financial activities incorporating income and
expenditure account on a straight line basis over the lease term.
Employee benefits
When employees have rendered service to the charity, short-term employee benefits to which the employees
are entitled are recognised at the undiscounled amount expected lo be paid in exchange for that service.
The charity operates a defined contribution plan for the benefit of ils employees. Contributions are expensed as
they become payable.
Flnanclal Instruments
The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments.
Basic financial instruments are initially recognised al transaction value and subsequently measured at their
selllemenl value with the exception of bank loans which are subsequently measured al amortised cost using the
effective interest method.
Going concern
The financial slalements have been prepared on a going concern basis as the Iruslees believe that no material
uncertainties exist. The Iruslees have considered the level of funds held and the expected level of income and
expenditure for 12 months from authorising these financial slalements. The budgeted income and expenditure
is sufficient with the level of reserves for the charity lo be able lo continue as a going concern.
19

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
DONATIONS AND LEGACIES
2025
2024
Donations
Legacies
294.851
296.533
268,845
628,031
591,384
896,876
INCOME FROM CHARITABLE ACTIVITIES
2025
2024
Activity
Infomalion and Support
Subscriptions
89,437
89,742
4 OTHER TRADING ACTIVITIES
2025
2024
Fundraising events
Other income
Trading income
33.867
20,586
597
11,534
17.078
51,785
32,717
5 INVESTMENT INCOME
2025
2024
Investment income
161,983
98,969
20

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
EXPENDITURE
2025
2024
DIRECT COSTS OF CHARITABLE ACTIVITIES
Staff costs
Grants payable (see note 81
Contractors
Printing magazines
Subscriptions
Magazine contractors
Medical literature
323.032
306.370
94.281
63.631
7.286
30.904
2.800
30,900
189,654
164,828
46,261
56,068
12,035
29,999
411
54,671
Campaigns
TOTAL DIRECT COSTS
859,204
553,927
Support costs {see note 71
254.518
223,413
TOTAL CHARITABLE COSTS
1113722
777,340
FUNDRAISING COSTS
Direct
Support costs {see note 71
95.106
26.814
64,336
23,568
121.920
87,904
TOTAL EXPENDITURE
1235 642
865,244
21

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
7 SUPPORT COSTS
Basis for
allocation
2025
Charitable
Fundraising Governance
Total
staff costs
Postage, telephone and
slalionery
Office expenses
IT costs
Irrecoverable VAT
Depreciation
Interest payable
Professional fees
Other costs
Time spent
109,894
12,210
6.427
128.531
Pro rata usage
Pro rata usage
Pro rata usage
Pro rats usage
Pro rats usage
Pro rata usage
Pro rata usage
Pro rata usage
21.677
6,746
24,797
20,364
11,423
6,336
17,814
22,290
2,408
749
2,755
2,263
1.269
704
1,979
2,477
24.085
7.495
27,552
22,627
12,692
6,750
26,543
24,767
241341
281332
Governance costs
254,518
26.814
281.332
Basis for
allocation
Charitable
Fundraising Govornanco
Total
2024
Staff costs
Postage, telephone and
stationery
Office expenses
IT costs
Irrecoverable VAT
Depreciation
Interest payable
Professional fees
Other costs
Time spent
114,411
12,712
6,691
133,814
Pro rats usage
Pro rats usage
Pro mta usage
Pro ￿ta usage
Pro rata usage
Pro rata usage
Pro rata usage
Pro rata usage
17,904
7,014
19,796
20,228
10,728
7,287
2,206
12,548
1,989
779
2,200
2,247
1,192
810
245
1,394
19,893
7,793
21,996
22,475
11,920
8,097
7,051
13,942
4,600
212,122
11,291
223,413
23,568
11,291
11,291
246,981
Governance costs
23,568
246,981
22

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
8 GRANTS PAYABLE
2025
2024
General Fund
DePaul'. Developing Consensus Research Definition.. Jason
ELAROS.. MEA Clinical Assessment Toolkit App.. Phase11.' O'Brien
Exeler.. MEA Count ME In Survey Analysis.. Dawes
Liverpool.. Auricular Vagus Nerve Stimulation.. PhD'. Leslie
Manchester.. MEA Clinical Assessment Toolkil.. Phase11.' Tyson
Manchester.. Physician-caused Distress and Trauma.. Geraghty
Other
5.589
7.000
16,596
2,982
2.503
9.958
3.500
440
Ramsa
Fund
British Columbia.. Low Dose Naltrexone Clinical Trial.. Nacul
Leeds.. Testing a Personalised Dysautonomia Protocol. Sivan
LSHTM". UK MEICFS Biobank Operational Costs". Nacul
Manchester. MEA Clinical Assessment Toolkit. Phase l." Tyson
Newcastle." FaMEly Pregnancy Study." Stage l." Pearce
Surrey". Electrophysiology of MEICFS". Phase l.. Labeed
Other
98,939
49,908
88,636
21,756
7,470
11,111
91,760
21,757
14,940
16,103
250
306 370
164,828
9 AUDITOR'S REMUNERATION
2025
2024
Fees payable to the charity's auditor for the audit of the charity's
annual accounts
6.750
4,600
10 NET INCOMEIIEXPENDITUREI
Net incomellexpendilurel is slated after chargingllcrediting}'.
2025
2024
Audilorfs remuneration
Depreciation - owned assets
Equipment hire
6.750
12.692
2.345
4,600
11,920
630
23

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDEO 31 DECEMBER 2025
11 TRUSTEES, REMUNERATION ANO BENEFITS
There was no trustees. remuneration or other benefits for the year ended 31 De￿mber 2025 nor for the year
ended 31 December 2024.
Trustees. expenses
During current year six Trustees received reimbursement of expenses amounting to £6,470 12024.. four
Trustees re￿iVed £6,568).
12 STAFF COSTS
2025
2024
Wages and salaries
Social security costs
Other pension costs
463,618
39,706
16,039
344,284
21,704
9,815
519,363
375,803
The average number of employees during the year was as follows..
2025
21
2024
15
Average employees
The Key Management Personnel of the charity are represented by the trustees, who are not remunerated.
13 TANGIBLE FIXED ASSETS
Leasehold
Fixtures
property and fittings
Computer
equipment
Totals
COST
At 1 January 2025
Additions
At 31 December 2025
177,712
2,482
18,405
198,599
177 712
200.550
DEPRECIATION
Al 1 January 2025
Charge for the year
At 31 December 2025
79,971
8,886
2,400
82
9,637
3,724
92,008
12,692
104700
NET BOOK VALUE
At 31 December 2025
At 31 December 2024
97,741
82
8,768
106,591
24

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDEO 31 DECEMBER 2025
14 STOCKS
2025
2024
stocks
9.466
7,881
15 DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025
2024
Other debtors
Tax recoveoble
Legacies
Prepayments and accrued income
7,176
3,249
59,221
61,150
4,397
2,945
361,477
10,678
130,796
379,497
16 CURRENT ASSET INVESTMENTS
2025
2024
Term deposits
2.072.213
2,278,750
17 CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025
2024
Trade creditors
Social security and other taxes
Other creditors
Grant commitments
Accruals and deferred income
12.006
10.862
28.145
49.908
40.597
10,867
7,457
33,118
21,757
45,588
141.518
118,787
Oeferred income
Deferred income represents deferred annual membership subscriptions.
2025
2024
Deferred income al 1 January
Resources deferred during the year
Amounts released from previous years
Deferred income al 31 De￿mber
40.723
40,597
140.7231
40.597
37,860
40,723
137,8601
40,723
25

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDEO 31 DECEMBER 2025
18 MOVEMENT IN FUNDS
Net Transfers
movement
between
in funds
funds
At 1.1.25
At 31.12.25
Unrestricted funds
General Fund - Unreslricled
Designated Fund - Sinking Fund
Designated Fund - Core Services
Designated Fund - Research Project
Designated Fund - Healthcare Research
Designated Fund - Fixed Assets
1.326,948
10,000
550,000
1,200,000
1182.258)
414,150
5,000
1550,0001
1200,0001
235,000
95,850
1.558.840
15.000
1.000.000
235.000
95.850
2,904,690
3,086,948
1182,2581
Restricted funds
Ramsay Research Fund
774,922
1158,7951
616,127
TOTAL FUNDS
3 861870
341053
3.520.817
Nel movement in funds, included in the above are as follows..
Movement
in funds
Income Expenditure
Unrestricted funds
General Fund - Unreslricled
775.5PA
1957,8221
(182.2581
Restricted funds
Ramsay Research Fund
119,025
1277,8201
1158,7951
TOTAL FUNDS
894,589
1,235,642
341053
26

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDEO 31 DECEMBER 2025
18 MOVEMENT IN FUNDS Icontinuedl
Comparatives for movement in funds
Net
movement
in funds
Transfers
between
funds
At 1.1.24
At 31.12.24
Unrestricted funds
General Fund - Unreslricled
Designated Fund - Sinking Fund
Designated Fund - Core Services
Designated Fund - Research Project
2,335,428
5,000
490,500
256,020 11,264,500)
5,000
59,500
1,200,000
1,326,948
10,000
550,000
1,200,000
3,086,948
2,830,928
256,020
Restricted funds
Ramsay Research Fund
777,882
(2,9601
774,922
TOTAL FUNDS
3,608,810
253,060
3,861,870
Nel movement in funds, included in the above are as follows..
Movement
in funds
Income Expenditure
Unrestricted funds
General Fund - Unreslricled
976,454
1720,4341
256,020
Rostricted funds
Ramsay Research Fund
141,850
1144,8101
12,9601
TOTAL FUNDS
1,118,304
1865,2441
253,060
27